Real‐world outcome of crizotinib for anaplastic lymphoma kinase‐positive lung cancer: Multicenter retrospective analysis in South Korea

Real‐world outcome of crizotinib for anaplastic lymphoma kinase‐positive lung cancer: Multicenter retrospective analysis in South Korea

Abstract Background About 3%–5% of non‐small cell lung cancer (NSCLC) presents positive anaplastic lymphoma kinase (ALK). Recently, several target agents have been approved as a treatment for ALK‐positive NSCLC. This study aimed to analyze the real‐world efficacy and outcome when administered crizot...

Full description

Bibliographic Details
Main Authors: Da Som Jeon, Cheol‐kyu Park, Seung Joon Kim, Chan Kwon Park, Yoon Soo Chang, Chi Young Jung, Sung Yong Lee, Shin‐Yup Lee, Jeong‐Seon Ryu, Jeong Eun Lee, Kye Young Lee, Tae Won Jang, Seung Hun Jang, Seong Hoon Yoon, Sang Hoon Lee, Chang‐min Choi, Hyeong Ryul Kim, Yeon Joo Kim
Format: Article
Language:English
Published: Wiley 2024-02-01
Series:Thoracic Cancer
Subjects:
adverse events
anaplastic lymphoma kinase
crizotinib
non‐small cell lung carcinoma
progression‐free survival
Online Access:https://doi.org/10.1111/1759-7714.15213

Internet

https://doi.org/10.1111/1759-7714.15213

Similar Items